Using REPRONEX®

You’ve been prescribed REPRONEX®, a purified hMG that can be administered by subcutaneous (SC) or intramuscular (IM) injection. REPRONEX® is used for the development of multiple follicles and ovulation induction in women who have previously received itinerary suppression.

Q•Cap™ is the only available vial adapter for needle-free reconstitution. It provides a convenient way to mix your medicines in just 1 syringe, for just 1 injection a day. There are no extra injections to worry about or additional administration methods to learn. Q•Cap™ eliminates stress, anxiety, and accidental needlesticks associated with traditional reconstitution, which increases your comfort level and that of your partner. And, importantly, Q•Cap™ helps build your confidence about reconstitution.

Q•Cap™ can only be used with Ferring fertility products, including BRAVELLE®, MENOPUR®, and REPRONEX®.

It’s natural to have concerns about your infertility treatment, so we’ve provided practical and detailed information about REPRONEX® that you may need, including:

Prescribing Information

Learn about possible side effects, contraindications, and other information found within the full Prescribing Information.

Injecting REPRONEX

Access helpful instructions for administering your subcutaneous or intramuscular injections.

REPRONEX FAQs

Find the answers to our most frequently asked questions about REPRONEX.

This information is provided as an educational service; if you have any questions, please don't hesitate to call your doctor or nurse.

REPRONEX®, in conjunction with hCG, is indicated for multiple follicular development (controlled ovarian stimulation) and ovulation induction in patients who have previously received pituitary suppression.

Important Safety Information

Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe REPRONEX®. REPRONEX®, like all gonadotropins, is a potent substance capable of causing mild to severe adverse reactions, including OHSS (incidence of 3.5%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. REPRONEX® is contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; the presence of any cause of infertility other than anovulation unless they are candidates for in-vitro fertilization; abnormal bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to menotropins; REPRONEX® is not indicated in women who are pregnant. There are limited human data on the effects of menotropins when administered during pregnancy.

Click here to see Full Prescribing Information for REPRONEX®.


Previous:
REPRONEX®
Next:
Injecting REPRONEX®

CONTACT   INTERNATIONAL   U.S.A.   |   TERMS & CONDITIONS
© 2007 Ferring Pharmaceuticals Inc.